Biological

Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 clinical trials

studies test it: 11
open now: 7
in phase 3: 0
first study started: 2020

Keep track of what changes. Save the Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

T3011: 8

Combined with it in one product

T3011 + pembrolizumab: 1
T3011 + Cobimetinib: 1

Studies by the year they started

11 studies that test it; most in 2024 (4)

Studies that test Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011, by start year
Year	Studies
2020	2
2021	1
2022	1
2023	2
2024	4
2025	1

By phase

A phase 1/2 study counts in both.

Phase 1: 9
Phase 2: 8

What it is tested for

Each study’s main condition, where its own words name it.

Colorectal Neoplasms: 2
Melanoma: 2
Endometrial Neoplasms: 1
Ascites: 1
Esophageal Neoplasms: 1
Mesothelioma: 1

Who runs them

Industry 8 · Other 3

ImmVira Pharma Co. Ltd (6) · Shanghai Pharmaceuticals Holding Co., Ltd (2) · West China Hospital (2) · China Medical University, China (1)

Often tested with

Tested in the same studies.

Regorafenib (2) · Toripalimab (1) · Pembrolizumab (1) · Cobimetinib (1)

Studies

Open first, then newest update. How each study uses Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 is read from its arms, and is right about nine times in ten.